Drug Profile
INO 1001
Alternative Names: INO-1001; Pardex; PARP inhibitors - RocketLatest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Developer Genentech; Inotek Pharmaceuticals
- Class Indoles; Vasoprotectives
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Abdominal aortic aneurysm; Acute lung injury; Erectile dysfunction; Glioblastoma; Malignant melanoma; Reperfusion injury
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 11 Jan 2011 INO 1001 is available for licensing as of 11 Jan 2011. http://www.inotekcorp.com
- 11 Jan 2011 Discontinued - Phase-I for Abdominal aortic aneurysm in USA (Parenteral)